439 related articles for article (PubMed ID: 32864784)
21. COVID-19 and renin-angiotensin system modulators: what do we know so far?
de la Cruz A; Ashraf S; Vittorio TJ; Bella JN
Expert Rev Cardiovasc Ther; 2020 Nov; 18(11):743-748. PubMed ID: 32842817
[TBL] [Abstract][Full Text] [Related]
22. Drugs acting on the renin-angiotensin system and SARS-CoV-2.
Vitiello A; Pelliccia C; Ferrara F
Drug Discov Today; 2021 Apr; 26(4):870-874. PubMed ID: 33486116
[TBL] [Abstract][Full Text] [Related]
23. Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study.
Lim JH; Cho JH; Jeon Y; Kim JH; Lee GY; Jeon S; Noh HW; Lee YH; Lee J; Chang HH; Jung HY; Choi JY; Park SH; Kim CD; Kim YL; Kim SW
Sci Rep; 2020 Nov; 10(1):20250. PubMed ID: 33219294
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin-converting enzyme 2 as a versatile player in the management of coronavirus disease 2019.
Amano T
J Diabetes Investig; 2020 Sep; 11(5):1120-1122. PubMed ID: 32657484
[No Abstract] [Full Text] [Related]
25. Covid-19 and cardiovascular risk: Susceptibility to infection to SARS-CoV-2, severity and prognosis of Covid-19 and blockade of the renin-angiotensin-aldosterone system. An evidence-based viewpoint.
Cappuccio FP; Siani A
Nutr Metab Cardiovasc Dis; 2020 Jul; 30(8):1227-1235. PubMed ID: 32595085
[TBL] [Abstract][Full Text] [Related]
26. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
Choudhury A; Mukherjee S
J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
[TBL] [Abstract][Full Text] [Related]
27. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
[TBL] [Abstract][Full Text] [Related]
28. Increased complications of COVID-19 in people with cardiovascular disease: Role of the renin-angiotensin-aldosterone system (RAAS) dysregulation.
Augustine R; S A; Nayeem A; Salam SA; Augustine P; Dan P; Maureira P; Mraiche F; Gentile C; Hansbro PM; McClements L; Hasan A
Chem Biol Interact; 2022 Jan; 351():109738. PubMed ID: 34740598
[TBL] [Abstract][Full Text] [Related]
29. Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure.
Razeghian-Jahromi I; Zibaeenezhad MJ; Lu Z; Zahra E; Mahboobeh R; Lionetti V
Heart Fail Rev; 2021 Mar; 26(2):371-380. PubMed ID: 32844337
[TBL] [Abstract][Full Text] [Related]
30. Covid-19: the renin-angiotensin system imbalance hypothesis.
Lanza K; Perez LG; Costa LB; Cordeiro TM; Palmeira VA; Ribeiro VT; Simões E Silva AC
Clin Sci (Lond); 2020 Jun; 134(11):1259-1264. PubMed ID: 32507883
[TBL] [Abstract][Full Text] [Related]
31. COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system.
Rysz S; Al-Saadi J; Sjöström A; Farm M; Campoccia Jalde F; Plattén M; Eriksson H; Klein M; Vargas-Paris R; Nyrén S; Abdula G; Ouellette R; Granberg T; Jonsson Fagerlund M; Lundberg J
Nat Commun; 2021 Apr; 12(1):2417. PubMed ID: 33893295
[TBL] [Abstract][Full Text] [Related]
32. Foe and friend in the COVID-19-associated acute kidney injury: an insight on intrarenal renin-angiotensin system.
Xu C; Chen Y; Yu J
Acta Biochim Biophys Sin (Shanghai); 2022 Jan; 54(1):1-11. PubMed ID: 35130610
[TBL] [Abstract][Full Text] [Related]
33. Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic.
Dworakowska D; Grossman AB
J Physiol Pharmacol; 2020 Apr; 71(2):. PubMed ID: 32633235
[TBL] [Abstract][Full Text] [Related]
34. ACE/ACE2 balance might be instrumental to explain the certain comorbidities leading to severe COVID-19 cases.
Bank S; De SK; Bankura B; Maiti S; Das M; A Khan G
Biosci Rep; 2021 Feb; 41(2):. PubMed ID: 33442728
[TBL] [Abstract][Full Text] [Related]
35. Hypertension, a Moving Target in COVID-19: Current Views and Perspectives.
Savoia C; Volpe M; Kreutz R
Circ Res; 2021 Apr; 128(7):1062-1079. PubMed ID: 33793331
[TBL] [Abstract][Full Text] [Related]
36. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.
Ramasamy S; Subbian S
Clin Microbiol Rev; 2021 Jun; 34(3):. PubMed ID: 33980688
[TBL] [Abstract][Full Text] [Related]
37. Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality.
Stafford EG; Riviere JE; Xu X; Kawakami J; Wyckoff GJ; Jaberi-Douraki M
J Am Pharm Assoc (2003); 2020; 60(6):e145-e152. PubMed ID: 32561317
[TBL] [Abstract][Full Text] [Related]
38. The concern about ACE/ARB and COVID-19: Time to hold your horses!
Pergolizzi JV; Varrassi G; Magnusson P; LeQuang JA; Leopoulou M; Paladini A; Taylor R; Wollmuth C; Breve F;
J Am Pharm Assoc (2003); 2020; 60(6):e88-e90. PubMed ID: 32747165
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology.
Vieira C; Nery L; Martins L; Jabour L; Dias R; Simões E Silva AC
Curr Drug Targets; 2021; 22(3):254-281. PubMed ID: 33081670
[TBL] [Abstract][Full Text] [Related]
40. ACE2 and SARS-CoV-2: Tissue or Plasma, Good or Bad?
Wenzel UO; Kintscher U
Am J Hypertens; 2021 Apr; 34(3):274-277. PubMed ID: 33151267
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
